This section provides various financial ratios derived from the company's financial statements to help assess its performance and financial health. Below are Current Ratio, Quick Ratio, Cash Ratio, Debt to Asset Ratio, Net Profit Margin, Return on Equity for LYEL as of 2026-03-31.
| Financial Ratios | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Return on Equity | -8.917 | -56.68 | -11.759 | -14.313 |
| Net Profit Margin | -1,220,200 | -2,344,700 | -258,013.333 | -534,812.5 |
| Debt to Asset Ratio | 21.95 | 27.011 | 19.326 | 22.449 |
| Cash Ratio | 245.676 | 121.794 | 387.65 | 267.74 |
| Quick Ratio | 723.48 | 528.088 | 1,029.553 | 764.745 |
| Current Ratio | 723.48 | 528.088 | 1,029.553 | 764.745 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)